MORGAN STANLEY PLC/CALL/AMGEN/310/0.1/20.09.24 | Market Closed - Börse Stuttgart 02:42:01 2024-07-12 pm EDT | ||
| 2.83 EUR | +24.12% |
|
| Current month | +77.99% | ||
| 1 month | +177.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 2.83 | +24.12% |
| 24-07-11 | 2.28 | +16.92% |
| 24-07-10 | 1.95 | +25.00% |
| 24-07-09 | 1.56 | +4.70% |
| 24-07-08 | 1.49 | +2.76% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 02:42 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0BQB |
| ISIN | DE000MB0BQB4 |
| Date issued | 2022-11-09 |
| Strike | 310 $ |
| Maturity | 2024-09-20 (70 Days) |
| Parity | 10 : 1 |
| Emission price | 3.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.04 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.03 € |
| Spread % | 1.13% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
330.8
USD
Average target price
317.4
USD
Spread / Average Target
-4.06%
- Stock Market
- Warrants
- Warrant
